Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.24
GLAXF's Cash to Debt is ranked higher than
54% of the 1159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.17 vs. GLAXF: 0.24 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.08   Max: 0.85
Current: 0.24

0.08
0.85
Equity to Asset 0.11
GLAXF's Equity to Asset is ranked lower than
55% of the 1084 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. GLAXF: 0.11 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.37
Current: 0.11

0.11
0.37
Interest Coverage 5.23
GLAXF's Interest Coverage is ranked lower than
51% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.76 vs. GLAXF: 5.23 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 5.23

0.81
28.06
F-Score: 5
Z-Score: 2.17
M-Score: -2.90
WACC vs ROIC
7.11%
17.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 15.64
GLAXF's Operating margin (%) is ranked higher than
84% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. GLAXF: 15.64 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 15.64

1.68
36.94
Net-margin (%) 11.98
GLAXF's Net-margin (%) is ranked higher than
83% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. GLAXF: 11.98 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 11.98

5.76
23.94
ROE (%) 47.46
GLAXF's ROE (%) is ranked higher than
99% of the 1139 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.62 vs. GLAXF: 47.46 )
GLAXF' s 10-Year ROE (%) Range
Min: 17.3   Max: 153.51
Current: 47.46

17.3
153.51
ROA (%) 6.84
GLAXF's ROA (%) is ranked higher than
82% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.52 vs. GLAXF: 6.84 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.84   Max: 26.32
Current: 6.84

3.84
26.32
ROC (Joel Greenblatt) (%) 38.93
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 1165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. GLAXF: 38.93 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.44   Max: 141.62
Current: 38.93

5.44
141.62
Revenue Growth (3Y)(%) -4.10
GLAXF's Revenue Growth (3Y)(%) is ranked higher than
59% of the 940 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. GLAXF: -4.10 )
GLAXF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.1   Max: 91
Current: -4.1

-4.1
91
EBITDA Growth (3Y)(%) -18.40
GLAXF's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 851 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. GLAXF: -18.40 )
GLAXF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.4   Max: 85.9
Current: -18.4

-18.4
85.9
EPS Growth (3Y)(%) -17.90
GLAXF's EPS Growth (3Y)(%) is ranked higher than
60% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. GLAXF: -17.90 )
GLAXF' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.2   Max: 93.9
Current: -17.9

-30.2
93.9
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.40
GLAXF's P/E(ttm) is ranked higher than
85% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.00 vs. GLAXF: 26.40 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 26.4

10.16
40.41
Forward P/E 19.42
GLAXF's Forward P/E is ranked higher than
94% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 19.42 )
N/A
PE(NRI) 27.00
GLAXF's PE(NRI) is ranked higher than
86% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.20 vs. GLAXF: 27.00 )
GLAXF' s 10-Year PE(NRI) Range
Min: 10.17   Max: 41.19
Current: 27

10.17
41.19
P/B 18.80
GLAXF's P/B is ranked lower than
60% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. GLAXF: 18.80 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 20.44
Current: 18.8

5.48
20.44
P/S 3.20
GLAXF's P/S is ranked higher than
98% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. GLAXF: 3.20 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 3.2

1.94
4.9
PFCF 21.10
GLAXF's PFCF is ranked higher than
91% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3458.60 vs. GLAXF: 21.10 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 21.1

8.21
41.33
POCF 14.13
GLAXF's POCF is ranked higher than
91% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.77 vs. GLAXF: 14.13 )
GLAXF' s 10-Year POCF Range
Min: 6.64   Max: 20.67
Current: 14.13

6.64
20.67
EV-to-EBIT 27.03
GLAXF's EV-to-EBIT is ranked higher than
82% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.13 vs. GLAXF: 27.03 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 27.03

7.7
240.2
Shiller P/E 17.40
GLAXF's Shiller P/E is ranked higher than
96% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 17.40 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.82   Max: 20.59
Current: 17.4

10.82
20.59
Current Ratio 1.10
GLAXF's Current Ratio is ranked higher than
50% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. GLAXF: 1.10 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.8   Max: 1.72
Current: 1.1

0.8
1.72
Quick Ratio 0.79
GLAXF's Quick Ratio is ranked higher than
51% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. GLAXF: 0.79 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.66   Max: 1.32
Current: 0.79

0.66
1.32
Days Inventory 205.44
GLAXF's Days Inventory is ranked higher than
61% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.39 vs. GLAXF: 205.44 )
GLAXF' s 10-Year Days Inventory Range
Min: 151.23   Max: 321.53
Current: 205.44

151.23
321.53
Days Sales Outstanding 56.42
GLAXF's Days Sales Outstanding is ranked higher than
84% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.94 vs. GLAXF: 56.42 )
GLAXF' s 10-Year Days Sales Outstanding Range
Min: 54.62   Max: 112.93
Current: 56.42

54.62
112.93

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.50
GLAXF's Dividend Yield is ranked higher than
98% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. GLAXF: 5.50 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 6.07
Current: 5.5

2.72
6.07
Dividend Payout 1.41
GLAXF's Dividend Payout is ranked higher than
97% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 1.41 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.51   Max: 4.05
Current: 1.41

0.51
4.05
Dividend growth (3y) 1.90
GLAXF's Dividend growth (3y) is ranked higher than
69% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. GLAXF: 1.90 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 1.9

-12.6
20.8
Yield on cost (5-Year) 7.61
GLAXF's Yield on cost (5-Year) is ranked higher than
97% of the 693 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. GLAXF: 7.61 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.76   Max: 8.39
Current: 7.61

3.76
8.39
Share Buyback Rate 1.60
GLAXF's Share Buyback Rate is ranked higher than
94% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. GLAXF: 1.60 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 51.8   Max: -20
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
GLAXF's Price/DCF (Projected) is ranked higher than
93% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 1.60 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 3.62
Current: 1.6

0.94
3.62
Price/Median PS Value 1.10
GLAXF's Price/Median PS Value is ranked higher than
85% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. GLAXF: 1.10 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.77   Max: 4.32
Current: 1.1

0.77
4.32
Earnings Yield (Greenblatt) 3.70
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
77% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. GLAXF: 3.70 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 3.7

0.4
12.9
Forward Rate of Return (Yacktman) 5.63
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.86 vs. GLAXF: 5.63 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4   Max: 60.9
Current: 5.63

4
60.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina, GSK.Switzerland,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
Taking a Closer Look at GlaxoSmithKline Apr 22 2015 
British Stock Picks From Gurus During Q4 Mar 24 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Bestinfond Adds More Than a Dozen Foreign Stocks to Portfolio Mar 06 2015 
Causeway International Value Fund Adds 2 New Stocks Mar 03 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
Bestinfond's Top 5 New Buys During Q4 Feb 03 2015 
Can GlaxoSmithKline Continue Striving in the Face of World Challenges? Jan 30 2015 
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
Prescription for Glaxo: A New Boss? May 04 2015
Will Glaxo (GSK) Beat Earnings Estimates This Season? - Analyst Blog May 04 2015
Corporate diary: May 4 - May 8 May 04 2015
China Investigating Siemens' Business Practices May 04 2015
5 Stocks David Cameron Should Consider Buying: GlaxoSmithKline plc, BP plc, Vodafone plc, HSBC... May 04 2015
U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug May 01 2015
GSK expected to can capital return plan amid stagnant growth May 01 2015
5 Toxic Stocks to Sell in May May 01 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's 4 billion pound capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
The Real Reason HSBC Holdings plc Will Return To Hong Kong: Shareholders In Diageo plc And... May 01 2015
U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug Apr 30 2015
U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug Apr 30 2015
GSK wins approval for asthma drug; will be produced in Zebulon Apr 30 2015
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma Apr 30 2015
Glaxo gets OK to expand marketing of inhaler drug Apr 30 2015
Glaxo gets OK to expand marketing of inhaler drug Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK